<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20066739</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2219-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>14</Day></PubDate></JournalIssue><Title>World journal of gastroenterology</Title><ISOAbbreviation>World J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection.</ArticleTitle><Pagination><StartPage>201</StartPage><EndPage>209</EndPage><MedlinePgn>201-9</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the suitability of rupintrivir against Enterovirus 71 (EV71) induced severe clinical symptoms using computational methods.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The structure of EV71 3C protease was predicted by homology modeling. The binding free energies between rupintrivir and EV71 3C and human rhinovirus 3C protease were computed by molecular dynamics and molecular mechanics Poisson-Boltzmann/surface area and molecular mechanics generalized-born/surface area methods. EV71 3C fragments obtained from clinical samples collected during May to July 2008 in Shanghai were amplified by reverse-transcription and polymerase chain reaction and sequenced.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed that rupintrivir had favorable binding affinity with EV71 3C protease (-10.76 kcal/mol). The variability of the 3C protein sequence in isolates of various outbreaks, including those obtained in our hospital from May to July 2008, were also analyzed to validate the conservation of the drug binding pocket.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Rupintrivir, whose safety profiles had been proved, is an attractive candidate and can be quickly utilized for treating severe EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao-Nan</ForeName><Initials>XN</Initials><AffiliationInfo><Affiliation>Research Unit, Shanghai Public Health Clinical Center, Caolang Road 2901, Shanghai 201508, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Zhi-Gang</ForeName><Initials>ZG</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Ting</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Bi-Sheng</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yun-Wen</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Zheng-Hong</ForeName><Initials>ZH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Gastroenterol</MedlineTA><NlmUniqueID>100883448</NlmUniqueID><ISSNLinking>1007-9327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>47E5O17Y3R</RegistryNumber><NameOfSubstance UI="D010649">Phenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086042">3C Viral Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical><Chemical><RegistryNumber>RGE5K1Q5QW</RegistryNumber><NameOfSubstance UI="C118874">rupintrivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086042" MajorTopicYN="N">3C Viral Proteases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010649" MajorTopicYN="N">Phenylalanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="N">Pyrrolidinones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>1</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20066739</ArticleId><ArticleId IdType="pmc">PMC2806558</ArticleId><ArticleId IdType="doi">10.3748/wjg.v16.i2.201</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kr&#xe4;usslich HG, Nicklin MJ, Lee CK, Wimmer E. Polyprotein processing in picornavirus replication. Biochimie. 1988;70:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">2840974</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehl HH, Parsley TB, Ho TV, Semler BL. Processing of a cellular polypeptide by 3CD proteinase is required for poliovirus ribonucleoprotein complex formation. J Virol. 1997;71:578&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191087</ArticleId><ArticleId IdType="pubmed">8985386</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong LE, Walker PA, Porter AG. Human rhinovirus-14 protease 3C (3Cpro) binds specifically to the 5&#x2019;-noncoding region of the viral RNA. Evidence that 3Cpro has different domains for the RNA binding and proteolytic activities. J Biol Chem. 1993;268:25735&#x2013;25739.</Citation><ArticleIdList><ArticleId IdType="pubmed">8245010</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang W, Harris KS, Alexander L, Wimmer E. Interaction between the 5&#x2019;-terminal cloverleaf and 3AB/3CDpro of poliovirus is essential for RNA replication. J Virol. 1995;69:3658&#x2013;3667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189081</ArticleId><ArticleId IdType="pubmed">7745714</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ES, Lee WG, Yun SH, Rho SH, Im I, Yang ST, Sellamuthu S, Lee YJ, Kwon SJ, Park OK, et al. Development of potent inhibitors of the coxsackievirus 3C protease. Biochem Biophys Res Commun. 2007;358:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall MS, Jain RP, Vederas JC. Inhibitors of 3C cysteine proteinases from Picornaviridae. Curr Top Med Chem. 2004;4:1239&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15320724</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo CJ, Shie JJ, Fang JM, Yen GR, Hsu JT, Liu HG, Tseng SN, Chang SC, Lee CY, Shih SR, et al. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg Med Chem. 2008;16:7388&#x2013;7398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA. 1999;96:11000&#x2013;11007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, Matthews DA, Patick AK. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother. 2005;49:619&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71:391&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132408</ArticleId><ArticleId IdType="pubmed">16675037</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK. In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2007;51:4366&#x2013;4373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2167992</ArticleId><ArticleId IdType="pubmed">17908951</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother. 2005;49:2267&#x2013;2275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Shih SR, Chang TY, Tseng HY, Shih YF, Yen KJ, Chen WC, Shie JJ, Fang JM, Liang PH, et al. A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Anal Biochem. 2008;375:115&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">18190777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254673</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB 3rd, Snoeyink J, Richardson JS, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007;35:W375&#x2013;W383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933162</ArticleId><ArticleId IdType="pubmed">17452350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowie JU, L&#xfc;thy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science. 1991;253:164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">1853201</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;thy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature. 1992;356:83&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">1538787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 2006;65:712&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4805110</ArticleId><ArticleId IdType="pubmed">16981200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15116359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33:W368&#x2013;W371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160225</ArticleId><ArticleId IdType="pubmed">15980491</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan J, Miller J, Kollman PA, Case DA. Continuum solvent studies of the stability of RNA hairpin loops and helices. J Biomol Struct Dyn. 1998;16:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">10052623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohlke H, Case DA. Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf. J Comput Chem. 2004;25:238&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">14648622</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol. 2003;330:891&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">12850155</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33&#x2013;38, 27-28.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744570</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosimann SC, Cherney MM, Sia S, Plotch S, James MN. Refined X-ray crystallographic structure of the poliovirus 3C gene product. J Mol Biol. 1997;273:1032&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9367789</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J, Lycke E, Ahlfors K, Johnsson T, Wolontis S, von Zeipel G. Letter: New enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, and mouth disease. Lancet. 1974;2:112.</Citation><ArticleIdList><ArticleId IdType="pubmed">4136956</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva EE, Winkler MT, Pallansch MA. Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil. Emerg Infect Dis. 1996;2:231&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626804</ArticleId><ArticleId IdType="pubmed">8903236</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert GL, Dickson KE, Waters MJ, Kennett ML, Land SA, Sneddon M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J. 1988;7:484&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">2841639</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimaru Y, Nakano S, Yamaoka K, Takami S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child. 1980;55:583&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1627055</ArticleId><ArticleId IdType="pubmed">6254449</ArticleId></ArticleIdList></Reference><Reference><Citation>Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA. Enterovirus surveillance--United States, 1970-2005. MMWR Surveill Summ. 2006;55:1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341:929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CW, Wu CF, Hsiao NW, Chang CY, Li SW, Wan L, Lin YJ, Lin WY. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int J Antimicrob Agents. 2008;32:355&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126984</ArticleId><ArticleId IdType="pubmed">18701259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JS, Wang KC, Chiang LC. Sheng-Ma-Ge-Gen-Tang inhibited Enterovirus 71 infection in human foreskin fibroblast cell line. J Ethnopharmacol. 2008;119:104&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18601992</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008;89:2518&#x2013;2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai MT, Cheng YH, Liu YN, Liao NC, Lu WW, Kung SH. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob Agents Chemother. 2009;53:748&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2630644</ArticleId><ArticleId IdType="pubmed">19015331</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>